Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Feb 26, 2024; 16(2): 70-88
Published online Feb 26, 2024. doi: 10.4252/wjsc.v16.i2.70
Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects
Min Meng, Wei-Wei Zhang, Shuang-Feng Chen, Da-Rui Wang, Chang-Hui Zhou
Min Meng, Wei-Wei Zhang, Shuang-Feng Chen, Chang-Hui Zhou, Department of Central Laboratory, Liaocheng People’s Hospital, Liaocheng 252000, Shandong Province, China
Da-Rui Wang, Department of Clinical Laboratory, Liaocheng People’s Hospital, Liaocheng 252000, Shandong Province, China
Co-first authors: Min Meng and Wei-Wei Zhang.
Co-corresponding authors: Chang-Hui Zhou and Da-Rui Wang.
Author contributions: Meng M and Zhang WW contributed equally to this work. Meng M and Zhang WW collected the references, analyzed clinical trials, and drafted the manuscript; Zhou CH andChen SF contributed to the conception and design of the review; Zhou CH andWang DR critically and systemically revised the manuscript; and all authors read and approved the final manuscript. Zhou CH andWang DR contributed efforts of equal substance in the research process. The choice of these researchers as co-corresponding authors acknowledges and respects this equal contribution. In summary, we believe that designating Zhou CH andWang DR as co-corresponding authors of is fitting for our manuscript as it accurately reflects our team’s equal contributions, collaborative spirit, and diversity.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chang-Hui Zhou, MD, Doctor, Department of Central Laboratory, Liaocheng People’s Hospital, No. 67 Dongchang West Road, Liaocheng 252000, Shandong Province, China. zhouchanghui008@163.com
Received: November 30, 2023
Peer-review started: November 30, 2023
First decision: December 17, 2023
Revised: January 4, 2024
Accepted: January 29, 2024
Article in press: January 29, 2024
Published online: February 26, 2024
Processing time: 87 Days and 19.8 Hours
Core Tip

Core Tip: Pulmonary diseases across all ages threaten millions of people and have emerged as one of the major public health issues worldwide. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are superior for standardization and large-scale production for disease treatment. Herein, we provide a detailed summary of clinical trials and results related to the use of UC-MSCs in the treatment of lung diseases and explore in depth the challenges and opportunities faced in the clinical application of these cells.